About US
Contact us
-
ASCO: Merck's Keytruda targets Pfizer's shaky Sutent post-surgery use in kidney cancerSince 2017, Pfizer’s kinase inhibitor Sutent has been approved to help prevent tumors from returning in high-risk kidney cancer patients after surgery. But its efficacy and safety are far from ideal.2021/6/7
-
It had to happen: Ex-Celgene shareholders sue Bristol Myers Squibb for $6.4B in lost CVR cash, claiming 'blatant misconduct'It wasn’t so much a question of whetherBristol Myers Squibb would be taken to court by former Celgene shareholders. It was more a question of when. The answer came Thursday in U.S. District Court-Sou2021/6/7
-
Fierce Pharma Asia—Amgen-Kyowa Kirin eczema deal; J&J, Legend's CAR-T; CStone's PD-L1Amgen shelled out $400 million upfront for ex-Japan rights to Kyowa Kirin's anti-OX40 atopic dermatitis candidate. Johnson & Johnson and Legend Biotech's anti-BCMA CAR-T therapy turnedup more mul2021/6/3
-
Regeneron leaps ahead in COVID-19 antibody race, scoring FDA nod for lower dose and subcutaneous injectionWhen Eli Lilly gained emergency use approval for its COVID-19 antibody treatment last October, it was a major triumph for a company aiming to satisfy a desperate need around the world. But eight mont2021/6/3
-
AstraZeneca shuffles leadership ahead of megadeal close, tapping an Alexion CEO and bringing up a new CFOWith AstraZeneca's Alexion buyout due to close later this year, the British Big Pharma is summoningthe rare disease specialist'schief financial officer toits C-suite andtapping a new CEO for its priz2021/6/1
-
ASCO: Novartis' radiotherapy ambition takes a small hit as Lutathera relegated to 'clinically relevant' survival edgeRadiopharmaceuticals, along with cell and gene therapy, is one of the advanced drug platforms Novartis has pegged for long-term growth. But that ambition has hit a small setback. Lutathera, the fi2021/6/1
-
Biogen's $1B Swiss plant scores regulatory nod as drugmaker awaits pivotal FDA decision on aducanumabDespite a flurry of uncertainty surrounding Biogen’s Alzheimer's hopeful aducanumab, the company has forged ahead with its launch preparationsahead of a pending FDA decision. Now, itsSwiss manufactur2021/5/27
-
Apellis' PNH victory lap: Newly FDA-approved Empaveli helped patients without prior Soliris treatmentApellis Pharmaceuticals is taking a victory lap. Less than two weeks after the FDA approved Apellis’ C3 inhibitor pegcetacoplan, marketed as Empaveli, for patients with a rare blood disorder kn2021/5/27
-
With plant-based manufacturing platform, Medicago takes COVID-19 vaccine production into the greenhouseDuring the span of the COVID-19pandemic, mRNA vaccines have gone from being promising technology in the lab to blockbuster products in the real world.In the pandemic's second year,Medicago is hoping2021/5/24
-
Vectura, after reinventing itself as a CDMO, accepts $1.4B buyout offer from CarlyleA few short years after rebranding itself as a CDMO, inhalation specialist Vectura's pivot has paid off big time—courtesy ofprominent healthcare investment firm The Carlyle Group. Vectura has a2021/5/24